GIP or not GIP? That is the question.
Glucose-dependent insulinotropic polypeptide (GIP) is a gastrointestinal hormone that is released during a meal and facilitates the disposal of both glucose and fat. Because of the insulinotropic action of GIP, this hormone has been considered as a potential therapy of type 2 diabetes, where insulin secretion is inadequate. However, a recent study using GIP receptor knockout mice suggests that inhibition of GIP signalling might be a new target for anti-obesity drugs.
Kieffer
Timothy J
TJ
Departments of Physiology and Surgery, 2146 Health Sciences Mall, University of British Columbia, Vancouver, BC V6T 1Z3, Canada. tim.kieffer@ubc.ca
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D005749:Gastric Inhibitory Polypeptide / Q000502:physiology* / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D009765:Obesity / Q000188:drug therapy
D005749:Gastric Inhibitory Polypeptide